Introduction
Owing to the widespread use of combination antiretroviral therapy, the overall morbidity and mortality from HIV infection has decreased. However, HIV-infected patients continue to have a high risk of chronic kidney disease (CKD) and end-stage renal disease. Factors associated with CKD in the setting of HIV infection include inadequate control of HIV, hepatitis C coinfection, and traditional CKD risk factors such as hypertension and diabetes [1] . In addition, certain antiretroviral medications have been associated with CKD. A growing number of studies implicate tenofovir disoproxil fumarate (TDF), one of the most commonly prescribed and highly effective antiretroviral medications, with a higher risk of CKD relative to other antiretroviral medications [2, 3] . The mechanism of TDF-associated renal injury is thought to be because of mitochondrial dysfunction within the proximal tubular Because TDF causes proximal tubule damage out of proportion to damage at other parts of the kidney, there may be opportunities to detect changes in tubular health above and beyond elevations in serum creatinine or changes in proteinuria. One such consequence of TDF use may be metabolic acidosis, as evidenced by low serum bicarbonate concentrations. Metabolic acidosis is a well established, common complication of CKD [6] ; low serum bicarbonate concentrations are also associated with CKD progression [7, 8] . Furthermore, we have recently shown that in persons with relatively preserved kidney function, low serum bicarbonate concentrations are associated with the risk of development of CKD as well as a rapid decline in kidney function, independent of baseline estimated glomerular filtration rate (eGFR) or albuminuria [9, 10] . Although these findings may indicate that mild metabolic acidosis has a deleterious effect on kidney function, they may also signify that low serum bicarbonate concentrations are a subclinical marker of underlying renal tubular disease that is not detected by creatinine-based eGFR or by glomerular injury (albuminuria). Changes in bicarbonate concentrations may function as one component as a multifaceted strategy to predict and monitor kidney health in HIV-infect persons.
We are not aware of any large-scale studies that have investigated the association of TDF use with serum bicarbonate concentrations, and whether lower serum bicarbonate concentrations in persons using TDF are associated with more rapid loss of kidney function. We investigated these questions using a national sample of HIV-infected veterans who initiated antiretroviral therapy between 1997 and 2011 with long-term follow-up of changes in kidney function. We hypothesized that TDF use would be associated longitudinally with lower serum bicarbonate concentrations. In addition, we hypothesized that lower bicarbonate concentrations would be associated with CKD risk in the HIV-infected population and that the association of TDF use with CKD risk would be attenuated, in part, after accounting for changes in serum bicarbonate concentrations.
Methods
We analyzed kidney disease outcomes in a national sample of HIV-infected US veterans. Data sources used to assemble the cohort have been described elsewhere [11] . In brief, the Department of Veteran Affairs HIV Clinical Case Registry (CCR) actively monitored all HIVinfected people receiving care in the Department of Veterans Affairs nationally and automatically extracted demographic, clinical, laboratory, pharmacy, utilization, and death information from the Department of Veterans Affairs electronic medical record to a centralized database [12] .
Participants
The target population for this analysis was HIV-infected veterans who had no prior exposure to antiretroviral medications at the time they entered clinical care in the Veterans Health Administration system, and who subsequently received antiretroviral therapy followed by regular visits and laboratory monitoring. We focused on participants who initiated therapy during or after 1997 when combination antiretroviral therapy became standard of care. The initial visit was defined as the date of starting antiretroviral therapy. Participants were followed until January 1, 2011. We excluded participants with prevalent kidney failure (receipt of chronic dialysis treatment or kidney transplant), and those who did not have at least one plasma HIV RNA value, CD4
þ cell count, serum bicarbonate concentration, record of an outpatient visit, and at least two creatinine assessments after the initial visit. We required at least one serum bicarbonate measurement within 1 year of starting ART. A total of 16 070 HIV-infected veterans were included in the final analytic cohort.
Primary independent variables
The two primary independent variables evaluated in this study were TDF use and serum bicarbonate concentrations. TDF use was stratified into three categories: initial users (on TDF as part of their initial treatment regimen), later users (started TDF later in the course of their treatment), and never users. Serum bicarbonate concentrations were measured by standard clinical analyzers at each medical center without storage or freezing. Serum bicarbonate concentrations were analyzed both continuously and categorically, using the following categories to span the distribution with adequate resolution for each subgroup: less than 22, 22-23.9, 24-26.9, 27-29.9, and at least 30 mmol/l. 'Low' serum bicarbonate was defined as less than 22 mmol/l, as this threshold has been used in prior CKD studies [7, 13] .
Longitudinal change was estimated using subjectspecific slopes from linear mixed models. We then categorized the annual rate of bicarbonate changes into tertiles, defined as follows: decrease in bicarbonate, less than À0.125 mmol/l; stable, À0.125 to 0.085 mmol/l; and increase, more than 0.085 mmol/l per year.
Outcomes
The primary study outcomes were serum bicarbonate concentrations (mmol/l) and incident CKD. As a longitudinal outcome, bicarbonate was evaluated both continuously and as a dichotomous outcome, with low serum bicarbonate defined as less than 22 mmol/l [7, 13] .
We calculated eGFR using the Chronic-Kidney Disease Epidemiology Collaboration formula based on age, sex, race, and serum creatinine [14] . CKD was defined by two consecutive eGFR measurements less than 60 ml/min per 1.73 m 2 that were at least 3 months apart and not obtained during inpatient admissions. For the analysis of incident CKD, we excluded persons with eGFR at baseline of less than 60 ml/min per 1.73 m 2 .
Other measurements
We ascertained drug utilization in CCR medication files based on pharmacy-fill information. Medication exposure was used to define antiretroviral drug predictor variables and to identify individuals with chronic diseases based on validated algorithms [15, 16] . Previous work has demonstrated that Veterans Health Administration pharmacy data are comprehensive and reliable for assessing medication use [17] [18] [19] [20] [21] . Use of antiretroviral medications was defined as in previous reports [15, 17] .
Demographic information (age, sex, and race) from CCR was supplemented with Medicare database information. We defined comorbid conditions as described previously [15] . Covariates included diabetes, glucose, SBP, hypertension, high-density lipoprotein cholesterol, low-density lipoprotein-cholesterol, triglycerides, cardiovascular disease, smoking, BMI, angiotensin-converting-enzyme-inhibitor use, diuretic use, lung disease, and eGFR. HIV-related characteristics included CD4 þ T-cell count, HIV-RNA load, hepatitis C or B coinfection, and illicit drug use [15] . Analyses included the baseline values of nearly all covariates; however, CD4 þ cell count and HIV-RNA load were time-updated as in our prior analyses [2] .
Statistical analysis
Baseline demographic and clinical characteristics were summarized by categories of baseline serum bicarbonate concentrations.
We used linear mixed models to examine the associations of tenofovir use with longitudinal changes in serum bicarbonate, with random intercepts and slopes using a Toeplitz covariance structure. Interaction terms between tenofovir category and time were used to determine whether the rate of change in bicarbonate differed by category of TDF use (initial, later, or never). Multivariable-adjusted models included demographics, traditional cardiovascular disease risk factors, and HIVrelated factors, as listed above.
We then analyzed the association of cumulative antiretroviral medication exposure with risk of a low serum bicarbonate concentration (defined as <22 mmol/l). We used generalized estimating equations using a Poisson working model [22] to account for clustering from repeated events to determine relative risks. Participants with serum bicarbonate less than 22mmol/l at baseline were excluded from this analysis. Multivariable-adjusted models included the covariates listed previously. In addition, we evaluated antiretroviral agents simultaneously in the fully adjusted model using backward stepwise selection analysis to identify antiretroviral medications that were independently associated with low bicarbonate. In sensitivity analysis, models with and without CD4
þ cell count and HIV-RNA viral load were examined to determine the extent to which HIV disease severity mediated the effects of antiretroviral medications on incident low bicarbonate.
Lastly, we used Cox proportional hazards regression models to evaluate the association of serum bicarbonate concentration with the risk of CKD in those who never used TDF compared with those who used TDF initially or later. Separate models were constructed to compare the associations of baseline and time-updated bicarbonate levels, as well as changes in bicarbonate during follow-up, with risk of incident CKD. Baseline was defined as the time of first exposure to an antiretroviral medication regimen. Bicarbonate was modeled both continuously and categorically, using cutpoints listed above. Longitudinal change was estimated using subject-specific slopes from linear mixed models. Change was also categorized as stable, declining, or increasing, using tertiles to define categories. In sensitivity analyses, we evaluated the association of low bicarbonate (<22mmol/l) with risk of incident CKD events within 1 and 2 years, separately among TDF never users and users.
Analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, USA). This study was approved by the Committee on Human Research at the San Francisco Veterans Affairs Medical Center.
Results
From 1997 to 2011, there were 16 070 participants, and 5.1% had serum bicarbonate concentrations less than 22 mmol/l at the time of study entry. Overall, participants with the lowest serum bicarbonate concentrations were older, more often African-American, and had a higher prevalence of traditional CKD risk factors, lower CD4 þ cell counts and higher HIV-RNA concentrations, lower eGFR, and a higher prevalence of proteinuria ( Table 1) . The unadjusted 5-year event rates of CKD in TDF never users and TDF users were 7.2% [95% confidence interval (CI): 6.5, 8.0] and 11.4% (95% CI: 10.7, 12.2), respectively. The age-adjusted 5-year events rates of CKD in TDF never users and TDF users were 6.0% (95% CI: 5.4, 6.7) and 10.3% (95% CI: 9.6, 11.1), respectively.
We compared the trajectory of bicarbonate concentrations over time among participants who started TDF initially (n ¼ 5223, 33%), those who started TDF later (n ¼ 6467, 40%), and those who never used TDF (n ¼ 4380, 27%) (Fig. 1 ). Compared to initial or later TDF users, those who never used TDF had lower serum bicarbonate concentrations at baseline and had a more rapid decline in serum bicarbonate concentrations over time. Initial and later TDF users had similar serum bicarbonate concentrations at baseline; however, initial TDF users maintained stable bicarbonate concentrations during follow-up. By contrast, those who started TDF later had declining bicarbonate concentrations during follow-up, which later stabilized (Supplemental Table 1 , http://links.lww.com/QAD/A867). In unadjusted analysis, never TDF users had larger decreases on average in bicarbonate concentrations (À0.11 mmol/l per year; 95% CI: À0.16, À0.05; P ¼ <0.001), whereas the average annual changes for later TDF users and initial TDF users were À0.02 mmol/l per year (95% CI: À0.05, 0.01; P ¼ 0.18) and À0.004 mmol/l per year (95% CI: À0.06, 0.05, P ¼ 0.90), respectively. Antiretroviral agents showed differing associations with risk of low serum bicarbonate concentrations (< 22mmol/l) during follow-up (Table 2) . In unadjusted analysis, several antiretroviral agents including TDF, emtricitabine, ritonavir, and atazanavir were associated with a lower incidence of low bicarbonate concentrations, whereas efavirenz and stavudine were associated with a higher incidence. After multivariable adjustment for traditional and HIV-related risk factors, TDF showed the strongest independent association with a lower incidence of low bicarbonate concentrations (5% decreased risk per year of exposure). Lamivudine was also independently associated with a lower incidence of low bicarbonate concentrations, whereas efavirenz and stavudine were associated with higher incidence. When CD4 þ cell count and HIV-RNA viral load were removed from the adjusted model, the observed protective association of TDF showed no attenuation (relative risk 0.95, 95% CI: 0.93, 0.97, P < 0.001). Similarly, efavirenz and stavudine associations remained unchanged.
The association of bicarbonate concentrations with the risk of incident CKD was much weaker in TDF users relative to nonusers (test for interaction P < 0.02) ( Table 3 ). In TDF never users, lower baseline bicarbonate concentrations were associated with a significantly higher risk of incident CKD, even after controlling for traditional CKD risk factors and HIV-related factors. However, in TDF users, the association of baseline bicarbonate concentration with risk of incident CKD was much weaker and no longer statistically significant after multivariable adjustment. In an analysis of time-updated bicarbonate concentrations, associations of low bicarbonate concentrations with incident CKD were observed in both never TDF users and TDF users, but this effect was significantly stronger in never TDF users (test for interaction P < 0.04).
As a sensitivity analysis, we repeated these analyses using baseline bicarbonate concentrations, but restricted follow-up for incident CKD events to 1 and 2 years, respectively. For events occurring within 1 year, a bicarbonate concentration of less than 22 mmol/l was associated with a higher risk of incident CKD in never TDF users (unadjusted HR 2.84, 95% CI: 0.90-8.96, P ¼ 0.08) but not among TDF users (HR 0.86, 95% CI: 0.42-1.76, P ¼ 0.67). Similarly, for incident CKD events within 2 years, a bicarbonate concentration of less than 22 mol/l was associated with a higher risk of incident CKD in never TDF users (unadjusted HR 2.40, 95% CI: 1.18-4.86, P ¼ 0.02) but not in TDF users (HR 0.99, 95% CI: 0.60-1.63, P ¼ 0.98).
We then analyzed patterns of longitudinal changes in serum bicarbonate with risk of incident CKD (Table 4) . Among those who never used TDF, decreases in bicarbonate concentrations over time were strongly associated with increased risk of incident CKD. In fully adjusted models among those who never used TDF, each 1 mmol/l decrease in bicarbonate concentration was associated with a 67% increased risk of CKD. The association was much weaker in TDF users, among whom each 1 mmol/l decrease was associated with only a 9% increased risk of CKD (test for TDF by bicarbonate interaction: P ¼ 0.001). When we examined categories of change, we found that those with stable bicarbonate levels were least likely to develop CKD, whereas those with increasing or decreasing bicarbonate concentrations had higher CKD event rates. In fully adjusted analyses among TDF never users, those with decreasing or increasing bicarbonate had an 81 or 22% increased risk respectively, relative to those with stable levels. In TDF users, those with decreasing or increasing bicarbonate had a 25 or 21% increased risk, respectively.
Discussion
Lower serum bicarbonate concentrations have emerged as a risk factor for CKD in the general population, Tenofovir, serum bicarbonate, and CKD risk in the setting of HIV Kim et al. 1053 Table 2 . Association of cumulative antiretroviral medication exposure (per year) with incidence of low serum bicarbonate concentration (<22 mmol/l) in HIV-infected persons. independent of eGFR or albuminuria. Given the strong association of TDF with development of CKD and its known effects on kidney tubule health, we hypothesized that TDF use would be associated with reductions in bicarbonate concentrations over time. However, in this large, national cohort of HIV-infected persons on antiretroviral therapy, we found that participants using TDF had a lower incidence of reduced bicarbonate concentrations compared with those who never used TDF. Furthermore, while lower bicarbonate concentrations were strongly associated with incident CKD in those who never used TDF, we observed substantially weaker associations of bicarbonate concentrations with incident CKD in those using TDF. Although these results run counter to our a priori hypothesis; our findings suggest that TDF may alter the tubules' usual handling of bicarbonate in HIV-infected persons.
Metabolic acidosis, as manifested by low serum bicarbonate concentrations, is a common [6] complication of CKD and may contribute to the development of kidney disease. Such reductions in serum bicarbonate levels may trigger a compensatory increase in ammoniagenesis in the tubules, leading to inflammation by complement activation and structural damage to the kidney [7] . In small randomized trials in uninfected persons with CKD, serum bicarbonate supplementation has been shown to slow kidney disease progression [23] . Further study is needed to determine whether bicarbonate could be a modifiable risk factor for CKD onset and progression.
Given that the renal tubule is both the site of TDF toxicity and bicarbonate handling, we expected to find lower serum bicarbonate concentrations in persons using TDF and that low serum bicarbonate would be associated with CKD risk. To our surprise, neither of these hypotheses was confirmed. In contrast, we observed that TDF use was associated with higher bicarbonate concentrations and less decline in bicarbonate over time. Moreover, there was a strong association of low bicarbonate with CKD risk in TDF never users, but this association was much weaker in TDF users. The reasons for these findings are not clear and merits further investigation.
In the past, nucleoside analog reverse-transciptase inhibitors (NRTI) have been associated with type B lactic acidosis. Given this association, one may expect to observe a higher incidence of low bicarbonate concentrations in those on NRTIs as a result of lactic acidosis. However, in our analysis of antiretroviral agents, the NRTIs, except for stavudine, were in fact associated with a lower incidence of low serum bicarbonate concentrations. This finding is consistent with prior studies that have implicated stavudine most strongly with hyperlactatemia and lactic acidosis [24] . Furthermore, in comparison with other antiretroviral agents, TDF had the lowest incidence of low bicarbonate concentrations. Although the effect size was moderate, this difference highlights the unique impact of TDF on renal physiology.
The major strengths of our study are the large number of HIV-infected participants, the national representation, and the comprehensive capture of medications, comorbid conditions and laboratory values. Our sample size gave us adequate power to detect important effect modification and to determine associations within subgroups. Like nearly all large clinical studies of kidney disease, our study is limited by the inability to directly measure GFR. In addition, our study is not a randomized control trial and our observational cohort was comprised mainly of male veterans receiving regular medical care, which may limit generalization of our findings. Furthermore, while it is established that lower serum bicarbonate concentrations are a manifestation of metabolic acidosis in CKD, low bicarbonate can also represent compensation for a primary respiratory alkalosis. In HIV patients, who are Tenofovir, serum bicarbonate, and CKD risk in the setting of HIV Kim et al. 1055 Table 4 . Association of change in bicarbonate with risk of chronic kidney disease in tenofovir users and nonusers. prone to pulmonary and other infections, this compensatory process may be a confounder. Low bicarbonate may also be a manifestation of a pure lactic acidosis. Although we cannot distinguish between a pure lactic acidosis and an alternative metabolic acidosis, this uncertainty does not alter the strong association between bicarbonate concentration and CKD risk. Lastly, TDF users and nonusers may have had underlying differences not captured by our clinical data. For example, participants with worse kidney function at baseline may have not been prescribed TDF. We aimed to mitigate this possibility by separately evaluating those who were not on TDF at baseline but started TDF later as well as by adjusting for kidney function and CKD risk factors.
In conclusion, in this large cohort of HIV-infected veterans initiating antiretroviral therapy, TDF use was associated with higher serum bicarbonate concentrations longitudinally despite the known nephrotoxic effects of TDF. Furthermore, the strong associations of baseline and changes in bicarbonate with CKD risk in HIV-infected persons are obscured by the use of TDF. As a result, the role of bicarbonate concentration may be limited in optimizing a comprehensive strategy to monitor kidney health in the setting of TDF use in HIV-infected persons. Additional research should be pursued to understand the mechanism by which TDF disrupts the relationship of acidosis with CKD. Such investigation may provide further insight into how both TDF and metabolic acidosis may impair kidney function. Lastly with new antiretroviral therapies in development, including the prodrug tenofovir alafenamide fumarate [25] , it will be important to continue to investigate how they affect kidney function and its component processes including acid-base balance.
